Acute Porphyria Drug Database

Monograph

J04AK02 - Ethambutol
Not porphyrinogenic
NP

Rationale
Up to 90% of a dose is excreted as unchanged drug.
Therapeutic characteristics
Ethambutol is indicated for the treatment of infection with M. tuberculosis and some other mycobacteria. Less common side effects that can be potentially porphyrinogenic through reduction in carbohydrate intake and that also can be confused with an acute porphyria attack are loss of appetite, nausea, vomiting and anorexia.
Metabolism and pharmacokinetics
At least 70% and up to 90% of a dose is excreted unchanged primarily in urine and faeces. Up to 15% is excreted as inactive metabolites in urine. (Norsk legemiddelhåndbok and SPC). The metabolism appears to be oxidation to an aldehyde, followed by conversion to a dicarboxylic acid (DailyMed). Half-life elimination is 3-4 hours.
Published experience
Ethambutol is listed as safe (Moore 1997).

References

# Citation details PMID
*Scientific articles
1. DailyMed.
38563879
2. Drugs in the acute porphyrias--toxicogenetic diseases. Cell Mol Biol (Noisy-le-grand). 1997 Feb;43(1):89-94.
Moore MR, Hift RJ.
9074793
*Drug reference publications
3. Norsk legemiddelhåndbok. etambutol
*Summary of Product Characteristics
4. Norwegian medicines agency. Summary of Product Characteristics (SPC). Rimstar.

Similar drugs
Explore alternative drugs in similar therapeutic classes J04A / J04AK or go back.

Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia). Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway). What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.
Netherlands
Myambutol · Myambutol 400 mg filmomhulde tabletten · Myambutol 400 mg, filmomhulde tabletten · Myambutol, tabletten 400 mg
Belgium
Myambutol · Myambutol 400 mg compr. pellic.
United Kingdom
EMB-Fatol · EMB-Fatol 1g/10ml concentrate for solution for infusion vials · Ethambutol · Ethambutol 100mg tablets · Ethambutol 100mg/5ml oral solution · Ethambutol 125mg/5ml oral solution · Ethambutol 150mg/5ml oral solution · Ethambutol 150mg/5ml oral suspension · Ethambutol 200mg/5ml oral solution · Ethambutol 200mg/5ml oral suspension · Ethambutol 250mg/5ml oral solution · Ethambutol 250mg/5ml oral suspension · Ethambutol 25mg/5ml oral solution · Ethambutol 300mg/5ml oral solution · Ethambutol 300mg/5ml oral suspension · Ethambutol 350mg/5ml oral solution · Ethambutol 375mg/5ml oral solution · Ethambutol 400mg tablets · Ethambutol 400mg/5ml oral solution · Ethambutol 400mg/5ml oral suspension · Ethambutol 450mg/5ml oral solution · Ethambutol 500mg/5ml oral solution · Ethambutol 500mg/5ml oral suspension · Ethambutol 50mg/5ml oral solution · Ethambutol 600mg/5ml oral solution · Ethambutol 600mg/5ml oral suspension · Ethambutol 700mg/5ml oral solution · Ethambutol 700mg/5ml oral suspension
Denmark
Myambutol
Norway
EMB-Fatol · Myambutol
Poland
Ethambutol Teva
Luxembourg
MYAMBUTOL
Finland
Ethambutol Orion
Latvia
Amiobutols
 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙